Ryan Chandanais

Jan 3, 2024 | outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Peter H. Calcott |Ryan Chandanais |Louis Garguilo

Get more pharma outsourcing insight with our FREE newsletter Newsletter | January 3, 2024 BEST OF INDUSTRY INSIGHTSConnect With Outsourced Pharma:

Jan 2, 2024 | outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Peter H. Calcott |Ryan Chandanais |Louis Garguilo

Get more pharma outsourcing insight with our FREE newsletter Newsletter | January 2, 2024 BEST OF INDUSTRY INSIGHTSConnect With Outsourced Pharma:

Nov 1, 2023 | lifescienceleader.com | Ryan Chandanais

Magazine Article | November 1, 2023 Source: Life Science Leader By Ryan Chandanais The FDA employs various special designations to streamline and incentivize the advancement of drugs addressing medical gaps. While some designations can accelerate FDA timelines for NDAs and biologics license applications (BLAs), others may abbreviate the duration of clinical trials.

Oct 30, 2023 | outsourcedpharma.com | Ryan Chandanais |Aditi Shivarkar |Peter H. Calcott |Cory Lewis |Louis Garguilo

The FDA employs special designations to streamline and incentivize the advancement of drugs addressing medical gaps. While some designations can accelerate FDA timelines for NDAs and BLAs, others may abbreviate the duration of clinical trials. Let's look at each of the nine special designations and what scenarios or drugs/therapies are best suited for each.

Oct 12, 2023 | clinicalleader.com | Ryan Chandanais |Thomas Wicks

IRT has emerged as a critical component of clinical trials, streamlining operations and ensuring seamless trial management. However, selecting the right IRT supplier is a pivotal decision that wields substantial influence over patient safety, data integrity, and site compliance. Join us Oct 24th for the inaugural Clinical Leader Solutions Expo, a new clinical sourcing experience where leading IRT suppliers will showcase their latest technologies and solutions via a virtual, interactive platform.